Taysha Gene Therapies (TSHA) Accumulated Depreciation (2020 - 2026)

Taysha Gene Therapies has reported Accumulated Depreciation for 7 years, with the latest figure at $5.0 million in Q1 2026.

• Quarterly Accumulated Depreciation rose 30.28% year-over-year to $5.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.0 million (up 30.28% YoY) and the FY2025 annual result came in at $4.7 million, up 30.69% from the prior year.
• Accumulated Depreciation advanced to $5.0 million in Q1 2026 per TSHA's latest filing, from $4.7 million in the prior quarter.
• Over five years, Accumulated Depreciation peaked at $5.0 million in Q1 2026 and troughed at $754000.0 in Q1 2022.
• A 5-year average of $3.0 million and a median of $3.3 million in 2024 frame the typical range for Accumulated Depreciation.
• The sharpest annual moves came in 2022 and 2025: Accumulated Depreciation soared 1739.02% in 2022, then climbed 12.03% in 2025.
• Over 5 years, Accumulated Depreciation stood at $1.6 million in 2022, then surged by 81.43% to $3.0 million in 2023, then grew by 20.31% to $3.6 million in 2024, then jumped by 30.69% to $4.7 million in 2025, then advanced by 6.19% to $5.0 million in 2026.
• According to Business Quant data, Accumulated Depreciation over the past three periods registered $5.0 million, $4.7 million, and $4.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.